Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.49 |
| ▸ | CES1 | P23141 | 2/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | RHOA | P61586 | 1/20 | 0.46 |
| ▸ | VCP | P55072 | 1/20 | 0.45 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.44 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.43 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3300911 | 1.00 | NPC1 (0.58) | NPC1RAB9ANAMPTSLC18A3TDP1 | |
| Hydrochloric Acid SCHEMBL9347470 | 0.98 | NPC1 (0.57) | NPC1RAB9ANAMPTSLC18A3TDP1 | |
| Hydrochloric Acid SCHEMBL9347478 | 0.98 | NPC1 (0.57) | NPC1RAB9ANAMPTSLC18A3TDP1 | |
| SCHEMBL15911925 | 0.86 | SLC18A3 (0.57) | NAMPTSLC18A3TDP1CES1TRPV6 | |
| SCHEMBL1066991 | 0.86 | SLC18A3 (0.57) | NAMPTSLC18A3TDP1CES1TRPV6 | |
| SCHEMBL9347459 | 0.85 | NAMPT (0.50) | NPC1RAB9ANAMPTSLC18A3TDP1 | |
| SCHEMBL3543089 | 0.81 | MAPT (0.63) | NAMPTSLC18A3TDP1MAPT | |
| SCHEMBL3543093 | 0.81 | MAPT (0.63) | NAMPTSLC18A3TDP1MAPT | |
| SCHEMBL13389548 | 0.81 | SLC18A3 (0.61) | NAMPTSLC18A3CES1TRPV6PGR | |
| SCHEMBL3302063 | 0.81 | SLC18A3 (0.61) | NAMPTSLC18A3CES1TRPV6PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025072437-A1 | HETEROARYL COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | ALPHINA THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-16 | — | — | US | disclosed |
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-16 | — | — | US | disclosed |
| US-7795283-B2 | Oxadiazole derivative as DGAT inhibitors | ASTRAZENECA AB (SE) | 2010-09-14 | — | — | US | disclosed |
| US-7795283-B2 | Oxadiazole derivative as DGAT inhibitors | ASTRAZENECA AB (SE) | 2010-09-14 | — | — | US | disclosed |
| US-20100093733-A1 | AMIDE AND UREA DERIVATIVES FOR THE TREATMENT OF METABOLIC DISEASES | PROSIDION LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
| EP-0272580-B1 | Liquidcrystalline cyclohexylbenzene derivatives their manufacturing and novel nematic admixtures containing same | WOJSKOWA AKAD TECH (PL) | 1994-08-17 | — | — | EP | disclosed |
| CN-1022490-C | Liquid crystal mixture | BROTSKEY MILITARY TECHNOLOGY A (PL) | 1993-10-20 | — | — | CN | disclosed |
| CN-87101284-A | Preparation of liquid crystalline cyclohexylbenzene derivatives and novel nematic mixtures containing them | BROTSKEY MILITARY TECHNOLOGY A (PL) | 1988-12-14 | — | — | CN | disclosed |
| EP-0272580-A2 | Liquidcrystalline cyclohexylbenzene derivatives their manufacturing and novel nematic admixtures containing same | Wojskowa Akademia Techniczna im. Jaroslawa Dabrowskiego (PL) | 1988-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | DGAT1, DGAT2, GPR119 | NPC1 423/4885RAB9A 2923/4885NAMPT 165/4885 |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | DGAT1, DGAT2, GPR119 | NPC1 399/4885RAB9A 2977/4885NAMPT 161/4885 |
| US-20100093733-A1 | AMIDE AND UREA DERIVATIVES FOR THE TREATMENT OF METABOLIC DISEASES | CPS1, GOT2, GPR119 | NPC1 630/4885RAB9A 1908/4885NAMPT 1146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.